A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication.
Sarcopenia...

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...

The master regulator mTOR has made its mark as the target of dozens of drugs and clinical candidates for diseases ranging from cancer to diabetes, but David Sabatini thinks its full therapeutic value won’t be...

Nimbus Therapeutics LLC has shown one of its computationally designed acetyl-Coenzyme A carboxylase (ACC; ACAC) inhibitors, dubbed ND-646, can block the fatty acid synthesis that fuels growth of lung tumors, and has developed a biomarker...